
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of …